#United States #ADC #AbbVie #North Chicago #Solid Tumors

AbbVie to Unveil Promising Data at ESMO 2025

AbbVie, a prominent player in the oncology field, is excited to announce its presentation of new research data from its innovative antibody-drug conjugate (ADC) platform at the 2025 European Society for Medical Oncology (ESMO) Congress. This prestigious event will occur in Berlin, Germany, from October 17 to 21, 2025, gathering experts from around the globe to discuss advancements in cancer treatment.

The data will spotlight investigational and approved ADCs within AbbVie’s extensive portfolio, including telisotuzumab adizutecan (brand name Temab-A) and ABBV-706. These ADCs target complex and difficult-to-treat solid tumors, including pancreatic and colorectal cancers, addressing significant unmet medical needs for patients facing limited treatment options.

Dr. Daejin Abidoye, who leads AbbVie’s oncology division, emphasized the urgency of the situation for patients with advanced solid tumors. He stated, “Despite recent progress in treatment, there still exist pressing needs for improved options. The data we’ll present at ESMO highlights the strides we’re making through targeted therapies, showcasing our commitment to patient care.”

Key Highlights of the Presentation

AbbVie will deliver three major oral presentations centered around Temab-A, a next-gen ADC targeting c-Met with a novel payload designed to improve therapeutic outcomes. Here’s a glimpse at the encouraging results:

1. Combination Therapy in Colorectal Cancer: In a study involving biomarker-agnostic patients with advanced colorectal cancer who had undergone three or more previous treatments, the use of Temab-A in combination with bevacizumab (Bev) achieved an objective response rate (ORR) of 26.7%. In comparison, the current standard treatment yielded no responses. However, patients did experience Grade ≥3 adverse events at similar rates.

2. Monotherapy Success in MET-Amplified Solid Tumors: Among 100 enrolled patients with advanced MET-amplified solid tumors, Temab-A monotherapy yielded an impressive ORR of 46%. Notably, patients with non-small cell lung cancer saw even higher responses, averaging at 69%. The common side effects included anemia and neutropenia.

3. Promising Outcomes in Pancreatic Ductal Adenocarcinoma: In a trial focusing on patients with advanced pancreatic cancer, Temab-A showed an overall ORR of 24%. The rate increased to 40% among those previously treated with gemcitabine-nab-paclitaxel. Again, anemia emerged as a prominent toxic effect.

ABBV-706 Insights

AbbVie will also share findings from a Phase 1 analysis involving ABBV-706, another ADC aimed specifically at small cell lung cancer (SCLC). This study will analyze the drug’s potential to outperform platinum-based standard treatments, particularly in terms of progression-free survival. Early results highlight quick clearance of circulating tumor DNA (ctDNA), suggesting a promising biomarker for early treatment responses.

The ongoing Phase 2 study exploring ABBV-706 in tandem with atezolizumab will further investigate its efficacy by potentially replacing conventional chemotherapy protocols for SCLC patients.

Conclusion

As AbbVie prepares for its impactful presentations at ESMO 2025, the research it unveils promises to advance the understanding and treatment landscape of difficult solid tumors. The data will not only reinforce AbbVie's position as a leader in oncology but may also inspire future therapeutic strategies, paving the way for patients to receive more effective and targeted cancer treatments. The entire oncology community eagerly anticipates these groundbreaking revelations, which could significantly alter patient care approaches worldwide.